Identification of Cell Surface Targets Based on Gene Amplification/Overexpression

基于基因扩增/过表达的细胞表面靶点鉴定

• 批准号: 8244086
• 负责人: DAVID George BEER
• 金额: $ 20.37万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8244086
• 关键词: Acids; Address; Adenocarcinoma; Affect; Area; Barrett Esophagus; Binding; Biopsy; Biopsy Specimen; Blood Vessels; Candidate Disease Gene; Carcinoma in Situ; Cell Line; Cell Surface Proteins; Cell surface; Cells; Clinical; Columnar Epithelium; Combined Modality Therapy; DNA amplification; Databases; Development; Disease; Distal; Dysplasia; ERBB2 gene; Early Diagnosis; Endoscopy; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Esophageal; Esophageal Adenocarcinoma; Esophageal Tissue; Esophagogastric Junction; Esophagus; Event; Excision; Frequencies; Gastroesophageal reflux disease; Gene Amplification; Gene Expression; Gene Proteins; General Population; Genes; Genetic Predisposition to Disease; Goals; Health; Heterogeneity; Image; Immunohistochemistry; In Vitro; Incidence; Individual; Institution; Intestinal Metaplasia; Intestines; Label; Lead; Lesion; Light; Lymphatic Spread; MMP11 gene; MMP3 gene; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of esophagus; Membrane Proteins; Messenger RNA; Metaplasia; Methods; Michigan; Modality; Modeling; Molecular; Molecular Biology; Mucous Membrane; Neoplasms; Obesity; Operative Surgical Procedures; Outcome; Parents; Pathway interactions; Patients; Pattern; Penetrance; Peptides; Population; Premalignant; Principal Investigator; Proteins; Radiation; Reflux; Reverse Transcriptase Polymerase Chain Reaction; Risk; Roche brand of trastuzumab; Sampling; Screening for cancer; Sensitivity and Specificity; Sequence Analysis; Siblings; Societies; Spouses; Surface; Surveillance Methods; Survival Rate; Symptoms; Telomerase; Therapeutic; Therapeutic Intervention; Time; Tissue Microarray; Tissues; Translational Research; Universities; Validation; Western Blotting; base; cancer cell; cancer type; chemotherapy; colorectal cancer screening; expression vector; high risk; imaging modality; immunocytochemistry; improved; in vivo; innovation; meetings; molecular imaging; novel; optical imaging; overexpression; response; surveillance strategy; tumor

The incidence of adenocarcinoma of the distal esophagus and gastroesophageal junction has increased at an alarming rate of over 350% in the last few decades (1). This is among the greatest increase in incidence observed for any cancer type. When these cancers are detected early, patients have a relatively good outcome following surgical resection. The rapid vascular and lymphatic spread of this disease and the poor clinical response to radiation and chemotherapy, results in a poor outcome for most patients. Despite multimodal therapy, the 5-year survival rate for esophageal cancer remains dismal at only 5-15% (2,3). This highlights the importance of developing new methods for early cancer detection in patients with premalignant lesions such as Barrett's metaplasia and refining new treatment modalities to improve the survival of patients with this deadly disease. The presence of intestinal (Barrett's) metaplasia, a condition in which the normal squamous mucosa is replaced by columnar epithelium, is associated with esophageal adenocarcinoma (2-6). This disease is increased in obese individuals, a population rapidly expanding in the US and other Western societies. In patients with symptoms of acid reflux, Barrett's mucosa is found in ~10-12% at the time of initial endoscopy (5,6). Patients with Barrett's metaplasia have an estimated 30 to 40-fold greater risk of adenocarcinoma than the general population (3,4). The malignant potential of this condition is evidenced by the progression of non-dysplastic Barrett's metaplasia to low-grade dysplasia, high-grade dysplasia and finally to invasive adenocarcinoma. For this reason, patients with known Barrett's have regular endoscopic surveillance. Currently, surveillance is performed by white light endoscopy and random four-quadrant biopsy. However, in the esophagus, precancerous lesions are flat and endoscopically Indistinct from intesinal metaplasia, thus the sensitivity and specificity of this method is limited. Moreover, this method has not been shown to reduce the rate of progression of intestinal metaplasia to adenocarcinoma (7), thus, a new strategy for surveillance of Barrett's esophagus is critically needed. Although gastroesophageal reflux disease (GERD) and the development of metaplastic changes are recognized critical events, many specific molecular events underlying adenocarcinoma development remain incompletely understood (2-6). The idea that familial factors may be involved as an autosomaldominant pattern with incomplete penetrance has been hypothesized to underlie genetic predisposition (8). The development of GERD may also reflect another aspect of familial inheritance, as it is much more frequent in both affected sibling and parent pairs when compared to spouse controls (9). The tremendous molecular heterogeneity detected in esophageal adenocarcinomas suggests multiple pathways, or specific combinations of transforming events, may be occurring in individuals with Barrett's metaplasia and that lead to adenocarcinoma. The events associated with the development of both adenocarcinoma of the lower esophagus and the gastroesophageal junction, appear to be similar and may reflect the similar efiologies. The studies proposed in this application incorporate two integrated approaches to address the increasing clinical problem of esophageal adenocarcinoma. Using our SNP-array analyses of esophageal adenocarcinoma we will first search for the repertoire of nonrandom DNA amplification that occurs in this tumor type. We will then identify the genes localized within each amplified core region and those genes that encode surface proteins. Using our gene expression database for Barrett's metaplasia without dysplasia, Barrett's with low-grade dysplasia, high-grade dysplasia and invasive adenocarcinoma we will define those genes that are specifically over-expressed in cancer cells. Tissue microarrays and immunohistochemistry will be used to validate candidate gene protein over-expression. Validated candidate genes will be transfected and over-expressed in model cell lines to allow us to select specific peptides directed against these gene products. When fluorescently-labeled, these peptides can be topically administered onto the esophagus of high-risk patients during routine endoscopy to view large surface areas and to guide tissue biopsy. In vivo validation will be performed as described in Project 2. This approach has the potential to increase patient survival by detecting cancer at a point when it is most effectively treated. We now believe we have all of the components in place to make a rational plan of attack against a growing health problem.

在过去的几十年里，食管远端和胃食管交界处腺癌的发病率以超过350%的惊人速度增长(1)。这是在所有癌症类型中观察到的发病率增幅最大的癌症之一。当这些癌症被早期发现时，患者在手术切除后的预后相对较好。这种疾病的快速血管和淋巴扩散以及对放疗和化疗的不良临床反应导致大多数患者预后不佳。尽管采用多模式治疗，食管癌的5年生存率仍然很低，仅为5-15%（2,3）。这突出了开发新的方法来早期检测恶性肿瘤前病变（如巴雷特化生）和改进新的治疗方式以提高这种致命疾病患者的生存率的重要性。